Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study

Publication date: Available online 3 May 2018 Source:Brain, Behavior, and Immunity Author(s): Dorota Frydecka, Małgorzata Krzystek-Korpacka, Alba Lubeiro, Filip Stramecki, Bartłomiej Stańczykiewicz, Jan Aleksander Beszłej, Patryk Piotrowski, Kamila Kotowicz, Monika Szewczuk-Bogusławska, Edyta Pawlak-Adamska, Błażej Misiak We aimed to profile a broad panel of inflammatory markers in patients with schizophrenia and healthy controls. Additionally, we performed a meta-analysis of chemokine alterations that have not been subjected to quantitative synthesis so far. We recruited 78 patients with schizophrenia and 78 healthy controls, and measured inflammatory markers using the Luminex technology. After adjustment for multiple testing, we found elevated levels of interleukin(IL)-1 receptor antagonist (IL-1RA), IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, interferon-γ, eotaxin-1, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), platelet-derived growth factor with two B subunits (PDGF-BB), macrophage inflammatory protein (MIP)-1α, MIP-1β, vascular endothelial growth factor A (VEGF-A) and RANTES in multiple-episode schizophrenia (MES) patients. These differences, except for the difference in eotaxin-1 levels, appeared to be significant after co-varying for the dosage of antipsychotics. There were no significant differences in the levels of immune markers between first-episode schizophrenia (FES) patients and controls....
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research